DE69918072D1 - P53-regulierte gene - Google Patents

P53-regulierte gene

Info

Publication number
DE69918072D1
DE69918072D1 DE69918072T DE69918072T DE69918072D1 DE 69918072 D1 DE69918072 D1 DE 69918072D1 DE 69918072 T DE69918072 T DE 69918072T DE 69918072 T DE69918072 T DE 69918072T DE 69918072 D1 DE69918072 D1 DE 69918072D1
Authority
DE
Germany
Prior art keywords
genes
expression
regulated
bypassed
defects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918072T
Other languages
English (en)
Other versions
DE69918072T2 (de
Inventor
J Levine
E Murphy
H Mack
C Gish
Yat Tom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymetrix Inc
Princeton University
Original Assignee
Affymetrix Inc
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymetrix Inc, Princeton University filed Critical Affymetrix Inc
Application granted granted Critical
Publication of DE69918072D1 publication Critical patent/DE69918072D1/de
Publication of DE69918072T2 publication Critical patent/DE69918072T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69918072T 1998-03-27 1999-03-26 P53-regulierte gene Expired - Lifetime DE69918072T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/049,025 US6020135A (en) 1998-03-27 1998-03-27 P53-regulated genes
PCT/US1999/006656 WO1999050456A1 (en) 1998-03-27 1999-03-26 P53-regulated genes
US49025 2008-03-14

Publications (2)

Publication Number Publication Date
DE69918072D1 true DE69918072D1 (de) 2004-07-22
DE69918072T2 DE69918072T2 (de) 2005-07-07

Family

ID=21957674

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918072T Expired - Lifetime DE69918072T2 (de) 1998-03-27 1999-03-26 P53-regulierte gene

Country Status (9)

Country Link
US (3) US6020135A (de)
EP (1) EP1064404B1 (de)
JP (1) JP2002509732A (de)
AT (1) ATE269415T1 (de)
AU (1) AU3208599A (de)
CA (1) CA2324444A1 (de)
DE (1) DE69918072T2 (de)
HK (1) HK1038595A1 (de)
WO (1) WO1999050456A1 (de)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6355430B1 (en) * 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
WO2001062965A2 (en) * 2000-02-22 2001-08-30 Oxford Biomedica (Uk) Limited Differential expression screening method
US6884578B2 (en) * 2000-03-31 2005-04-26 Affymetrix, Inc. Genes differentially expressed in secretory versus proliferative endometrium
EP1282699B1 (de) * 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Spleisregion-antisensezusammensetzung und verfahren
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1297186A4 (de) * 2000-06-30 2005-06-29 Univ Utah Res Found Methode zum durchmustern für chemotherapeutische krebstherapien
US7567870B1 (en) * 2000-07-31 2009-07-28 Institute For Systems Biology Multiparameter analysis for predictive medicine
DE10037769A1 (de) * 2000-08-03 2002-02-21 Epigenomics Gmbh Diagnose von mit CD24 assoziierten Krankheiten
US6713257B2 (en) * 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US7108969B1 (en) * 2000-09-08 2006-09-19 Affymetrix, Inc. Methods for detecting and diagnosing oral cancer
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
DE10048633A1 (de) * 2000-09-25 2002-04-18 Schering Ag Methode zur in vitro Diagnostik von Endometriose
US6743897B1 (en) 2000-11-27 2004-06-01 Cytokinetics, Inc. Aspergillus fumigatus profilin
US6403372B1 (en) 2000-11-27 2002-06-11 Cytokinetics, Inc. Aspergillus fumigatus profilin
WO2002099140A1 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
ES2282444T3 (es) * 2001-06-05 2007-10-16 Auckland Uniservices Limited Metodo y composiciones para evaluar la funcion y los desordenes pulmo nares.
US6821737B2 (en) 2001-06-08 2004-11-23 Panomics, Inc. Method for screening for drug candidates for modulating transcription factor activity
US7981842B2 (en) 2001-06-08 2011-07-19 Panomics, Inc. Method for detecting transcription factor-protein interactions
US6924113B2 (en) 2001-06-08 2005-08-02 Panomics, Inc. Method and kit for isolating DNA probes that bind to activated transcription factors
US6696256B1 (en) 2001-06-08 2004-02-24 Pandmics, Inc. Method, array and kit for detecting activated transcription factors by hybridization array
US20040214166A1 (en) * 2001-06-08 2004-10-28 Xianqiang Li Method for identifying a disease state based on a detected mixture of activated transcription factors
US7343247B2 (en) * 2001-07-30 2008-03-11 The Institute For Systems Biology Methods of classifying drug responsiveness using multiparameter analysis
AU2002336410A1 (en) * 2001-08-29 2003-09-09 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
US20030157700A1 (en) * 2001-12-19 2003-08-21 Affymetrix, Inc. Apparatus and methods for constructing array plates
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
KR20060015446A (ko) * 2002-08-19 2006-02-17 윤 엔 간 질환의 치료 방법
US8008003B2 (en) 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP2006521793A (ja) * 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー
DE602004017426D1 (de) * 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
CA3084542A1 (en) 2003-06-10 2005-01-06 The Trustees Of Boston University Gene expression analysis of airway epithelial cells for diagnosing lung cancer
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
EP1644858B1 (de) 2003-07-10 2017-12-06 Genomic Health, Inc. Expressions-profil-algorithmus und test auf krebsprognose
EP2182063A3 (de) * 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulierung von EIF4E-Expression
WO2005040396A2 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR ASSAY SYSTEM FOR GENE EXPRESSION PROFILING
CA2551267C (en) * 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
US20050191682A1 (en) 2004-02-17 2005-09-01 Affymetrix, Inc. Methods for fragmenting DNA
ES2381644T3 (es) 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
EP2163650B1 (de) 2004-04-09 2015-08-05 Genomic Health, Inc. Genexpressionsmarker zur Vorhersage des Erfolgs von Chemotherapy
US20060073506A1 (en) 2004-09-17 2006-04-06 Affymetrix, Inc. Methods for identifying biological samples
WO2006034278A2 (en) * 2004-09-21 2006-03-30 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
US20060073511A1 (en) 2004-10-05 2006-04-06 Affymetrix, Inc. Methods for amplifying and analyzing nucleic acids
CA2584197A1 (en) * 2004-10-14 2006-04-27 Genentech, Inc. Cop1 molecules and uses thereof
CA2524964A1 (en) 2004-10-29 2006-04-29 Affymetrix, Inc. Automated method of manufacturing polymer arrays
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
AU2005304878B2 (en) * 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
DK1836629T3 (da) 2004-11-05 2020-05-18 Genomic Health Inc Forudsigelse af respons på kemoterapi ved anvendelse af markører for genekspression
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
EP3770278A1 (de) 2005-04-14 2021-01-27 The Trustees of Boston University Diagnose für lungenerkrankungen mittels klassenvorhersage
US20060269946A1 (en) * 2005-05-10 2006-11-30 Young Robert P Methods and compositions for assessment of pulmonary function and disorders
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
CA2608158A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
KR20080011292A (ko) * 2005-05-19 2008-02-01 시너젠즈 바이오사이언스 리미티드 유전자 다형 분석을 사용하여 폐암 발생 위험을 평가하는방법
WO2006123943A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
JP2009502253A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 関心の移動領域に対して放射線療法を施すシステムおよび方法
EP1907984A4 (de) * 2005-07-22 2009-10-21 Tomotherapy Inc Verfahren und system zur datenverarbeitung im rahmen eines strahlentherapiebehandlungsplans
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
EP1907058B1 (de) * 2005-07-22 2015-06-24 TomoTherapy, Inc. Verfahren zur positionierung von beschränkungen auf einer deformationsabbildung und system zur umsetzung
KR20080049716A (ko) 2005-07-22 2008-06-04 토모테라피 인코포레이티드 치료 계획의 전달과 관련된 퀄리티 보증 기준을 평가하는방법 및 시스템
JP2009502257A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド デリバーされた線量を評価するための方法およびシステム
US8229068B2 (en) * 2005-07-22 2012-07-24 Tomotherapy Incorporated System and method of detecting a breathing phase of a patient receiving radiation therapy
JP2009502252A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 生物学的モデルに基づいて放射線療法治療プランを適合させるための方法およびシステム
KR20080039920A (ko) * 2005-07-22 2008-05-07 토모테라피 인코포레이티드 방사선 치료 시스템에 의해 부여되는 선량을 평가하는시스템 및 방법
JP2009502254A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 医療デバイスの動作を監視するためのシステム及び方法。
JP5390855B2 (ja) 2005-07-23 2014-01-15 トモセラピー・インコーポレーテッド ガントリおよび治療台の協調した動きを利用した放射線療法の撮像およびデリバリー
WO2007028161A2 (en) * 2005-09-02 2007-03-08 The University Of Toledo Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2007044566A2 (en) * 2005-10-07 2007-04-19 Baylor Research Institute Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis
US7634363B2 (en) * 2005-12-07 2009-12-15 Affymetrix, Inc. Methods for high throughput genotyping
US7846664B2 (en) * 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
EP1969506A1 (de) * 2005-12-13 2008-09-17 Erasmus University Medical Center Rotterdam Genetische hirntumor-markierer
MX2008009592A (es) 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
EP2605018A1 (de) 2006-03-09 2013-06-19 The Trustees of the Boston University Diagnose- und Prognoseverfahren für Lungenerkrankungen mittels Genexpressionsprofilen aus Nasenepithelzellen
EP2389947A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008024114A1 (en) * 2006-08-24 2008-02-28 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia
WO2008048986A2 (en) * 2006-10-17 2008-04-24 Children's Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
WO2008100352A2 (en) 2006-11-03 2008-08-21 Baylor Research Institute Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
EP2253713B1 (de) 2008-03-11 2015-02-25 National Cancer Center Verfahren zur messung von kopiezahlen von chromosomen, genen oder speziellen nukleotidsequenzen mithilfe eines snp-arrays
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
ES2742251T3 (es) 2009-03-16 2020-02-13 Pangu Biopharma Ltd Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas
CA2757289A1 (en) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
PL2488873T3 (pl) 2009-10-16 2016-01-29 Novartis Ag Biomarkery odpowiedzi farmakodynamicznej wobec guza
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP2517020B1 (de) 2009-12-23 2015-10-21 Hill's Pet Nutrition, Inc. Zusammensetzungen und verfahren zur diagnostizierung und behandlung von nierenerkrankungen bei hunden
EA201201113A1 (ru) 2010-02-10 2013-03-29 Новартис Аг Способы и соединения для роста мышц
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
CN105820252B (zh) 2010-05-03 2020-07-21 Atyr 医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011256366C1 (en) 2010-05-17 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
EP2575857B1 (de) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von lysyl-trna-synthetasen
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
WO2011154139A2 (en) 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
JP6047489B2 (ja) 2010-08-12 2016-12-21 フェイト セラピューティクス，インコーポレイテッド 改善された造血幹細胞および前駆細胞療法
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6163104B2 (ja) 2010-11-15 2017-07-12 アクセラレイテッド・バイオサイエンシズ・コーポレーション ヒト・トロホブラスト幹細胞からの神経幹細胞の生成
EP2561102A1 (de) 2010-12-02 2013-02-27 Katholieke Universiteit Leuven K.U. Leuven R&D Eingriffe und diagnosen in zusammenhang mit der il-rezeptor-assoziierten kinase
EP3062108B1 (de) 2011-02-24 2019-06-19 Hill's Pet Nutrition, Inc. Verfahren zur diagnostizierung von nierenerkrankungen bei katzen
EP2680839A1 (de) 2011-03-02 2014-01-08 Morphotek, Inc. Gleichzeitige verabreichung von eribulin und farletuzumab zur behandlung von brustkrebs
SG10201601224WA (en) 2011-03-02 2016-03-30 Berg Llc Interrogatory cell-based assays and uses thereof
EP2685988A4 (de) 2011-03-15 2014-08-20 Univ North Carolina Verfahren zur behandlung von brustkrebs mit einer anthracyclintherapie
JP2014509515A (ja) 2011-03-18 2014-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンに対する応答を予測するための方法及び組成物
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
US10144969B2 (en) 2011-06-15 2018-12-04 Colgate-Palmolive Company Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
CA2857597A1 (en) 2011-11-30 2013-06-06 AbbVie Deutschland GmbH & Co. KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
CA2859149A1 (en) 2011-12-19 2013-06-27 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating hyperthyroidism in companion animals
EP3311847A1 (de) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
US11177020B2 (en) 2012-02-27 2021-11-16 The University Of North Carolina At Chapel Hill Methods and uses for molecular tags
CA2865575C (en) 2012-02-27 2024-01-16 Cellular Research, Inc. Compositions and kits for molecular counting
SG11201406201YA (en) 2012-04-02 2014-10-30 Berg Llc Interrogatory cell-based assays and uses thereof
AU2013243300B2 (en) 2012-04-05 2018-12-06 Oregon Health & Science University Gene expression panel for breast cancer prognosis
AU2013266419B2 (en) 2012-05-22 2018-09-27 British Columbia Cancer Agency Branch NANO46 genes and methods to predict breast cancer outcome
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
MX367366B (es) 2012-11-27 2019-08-16 Univ Pontificia Catolica Chile Composiciones y metodos para diagnosticar tumores de tiroides.
AU2013352307B2 (en) 2012-11-30 2018-11-15 Accelerated Biosciences Corp. Methods of differentiating stem cells by modulating miR-124
WO2014113804A1 (en) 2013-01-21 2014-07-24 Abbvie Inc. Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease
EP2962309B1 (de) 2013-02-26 2022-02-16 Accuray, Inc. Elektromagnetisch betätigter mehrblatt-kollimator
WO2014133855A1 (en) 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
EP3044332A1 (de) 2013-09-09 2016-07-20 British Columbia Cancer Agency Branch Verfahren und kits zur vorhersage des ergebnisses sowie verfahren und kits zur behandlung von brustkrebs mit strahlentherapie
GB2534315B (en) 2013-10-02 2020-08-05 Univ Leland Stanford Junior WNT compositions and methods for purification
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
DK3110973T3 (da) 2014-02-27 2019-05-13 Univ Leuven Kath Oxidativt stress og kardiovaskulære sygdomshændelser
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
JP2017516501A (ja) 2014-05-30 2017-06-22 ジーンセントリック ダイアグノスティクス， インコーポレイテッド 肺がんのタイピング法
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US11610644B2 (en) 2014-10-24 2023-03-21 Koninklijke Philips N.V. Superior bioinformatics process for identifying at risk subject populations
JP7065609B6 (ja) 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
DK3210142T3 (da) 2014-10-24 2020-11-16 Koninklijke Philips Nv Vurdering af tgf-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression
CA3148687A1 (en) 2014-11-26 2016-06-02 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
DK3234112T3 (da) 2014-12-19 2020-03-02 Univ Brussel Vrije In vitro-modning af et pattedyre-cumulus-oocytkompleks
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
EP3328440A4 (de) 2015-07-28 2019-01-16 Otonomy, Inc. Behandlung mit verkürzten trk-b- und trk-c-antagonisten
ES2861400T3 (es) 2015-08-14 2021-10-06 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de NFkB usando modelos matemáticos de la expresión de genes diana
US20180305748A1 (en) 2015-10-18 2018-10-25 Affymetrix, Inc. Multiallelic Genotyping of Single Nucleotide Polymorphisms and Indels
KR20170076480A (ko) 2015-12-24 2017-07-04 삼성전자주식회사 Pint 유전자의 발현 저해제 또는 pint의 활성 저해제를 포함하는 조성물 및 그의 용도
WO2017176652A2 (en) 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
CN109863251B (zh) 2016-05-17 2022-11-18 基因中心治疗公司 对肺鳞状细胞癌亚型分型的方法
CA3024747A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
EP3260552A1 (de) 2016-06-20 2017-12-27 Istituto Europeo di Oncologia (IEO) Verfahren und kits mit gensignaturen zur stratifizierung von brustkrebspatienten
WO2018013883A1 (en) 2016-07-14 2018-01-18 Caprion Proteomics Inc. Biomarkers of latent tuberculosis infection
EP3487874A1 (de) 2016-07-20 2019-05-29 Westfälische Wilhelms-Universität Münster Komplexspezifische standardisierung von immunologischen verfahren zur quantifizierung von s100a12
EP3655418A4 (de) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Verfahren zur behandlung von glioblastom
US11739386B2 (en) 2017-07-21 2023-08-29 Genecentric Therapeutics, Inc. Methods for determining response to PARP inhibitors
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
EP3461915A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären jak-stat1/2-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
EP3502279A1 (de) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären mapk-ap 1-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
ES2960914T3 (es) 2018-03-16 2024-03-07 Gopath Laboratories Llc Métodos para la detección personalizada de la reaparición del cáncer o de la metástasis y/o evaluación de la respuesta al tratamiento
CN113166767A (zh) 2018-09-05 2021-07-23 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 用于工程合成顺式调控dna的方法
CA3115922A1 (en) 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
WO2020104482A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma
EP4121534A1 (de) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
EP3907301A1 (de) 2020-05-08 2021-11-10 Istituto Europeo di Oncologia S.r.l. Methoden und kits zur bestimmung des risikos eines erneuten auftretens von brustkrebs
WO2023122758A1 (en) 2021-12-22 2023-06-29 Cornell University Prognostic/predictive epigenetic breast cancer signature

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810400D0 (en) * 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
DE69032864T3 (de) * 1989-03-29 2013-01-31 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
US5936079A (en) * 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
CA2118015A1 (en) * 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
US5858679A (en) * 1992-11-12 1999-01-12 Fornace, Jr.; Albert J. Method for determining the presence of functional p53 by measuring GADD45 protein expression
EP0931830B1 (de) * 1993-02-16 2001-03-07 Onyx Pharmaceuticals, Inc. Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
CN1141059A (zh) * 1993-11-22 1997-01-22 昂尼克斯药物公司 P53-结合多肽和编码该多肽的多核苷酸
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5667987A (en) * 1994-07-12 1997-09-16 Bristol-Myers Squibb Company P53 response genes
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US5702908A (en) * 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
CA2232000A1 (en) * 1995-09-14 1997-03-20 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
EP0859956B1 (de) * 1995-09-18 2003-07-02 Cancer Research Technology Limited Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen
AU8284198A (en) * 1997-07-02 1999-01-25 Board Of Regents, The University Of Texas System P53 as a regulator of cell differentiation
AU8382998A (en) * 1997-07-02 1999-01-25 Genzyme Corporation P53 influenced gene expression
DE19735221C1 (de) * 1997-08-14 1999-05-06 Wolfgang Willi Prof Dr Deppert Beeinflussung der Bindung von p53 an Zielgene
WO1999014356A2 (en) * 1997-09-17 1999-03-25 The Johns Hopkins University P53-induced apoptosis
AU9565598A (en) * 1997-09-26 1999-04-23 Board Of Trustees Of The University Of Illinois, The Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
US6297366B1 (en) * 1998-01-14 2001-10-02 Board Of Trustees Of The University Of Illinois ING-encoded p33ING1 protein as a mediator of p53 signaling pathway in mammalian cells
DE19847779C1 (de) * 1998-10-16 2000-02-03 Deutsches Krebsforsch p53-Bindungsregionen
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response

Also Published As

Publication number Publication date
HK1038595A1 (en) 2002-03-22
EP1064404B1 (de) 2004-06-16
WO1999050456A1 (en) 1999-10-07
ATE269415T1 (de) 2004-07-15
JP2002509732A (ja) 2002-04-02
CA2324444A1 (en) 1999-10-07
US6171798B1 (en) 2001-01-09
US6020135A (en) 2000-02-01
DE69918072T2 (de) 2005-07-07
EP1064404A1 (de) 2001-01-03
US20010039013A1 (en) 2001-11-08
AU3208599A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
DE69918072D1 (de) P53-regulierte gene
Beyer et al. Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes
EP0804548A4 (de) Ptc gene und ihre verwendung
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
DE60039072D1 (de) Verfahren zum screenen von mehrfach transformierteon von fluoreszenzproteinen
WO2001009301A3 (en) Nucleic acids and polypeptides of invertebrate twik channels and methods of use
ATE449837T1 (de) Abstammungs-spezifische zellen und vorläuferzellen
Gasri-Plotnitsky et al. A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity
ATE295888T1 (de) Genfallen-konstrukt zur identifizierung und isolierung von genen
ATE351905T1 (de) Mitogene regulatoren
WO1998005797B1 (en) Prostate cancer drug screening
ATE406094T1 (de) Identifizierung und charakterisierung von genen
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
Nakamura et al. The combination of ubiquitous transcription factors AP‐1 and Sp1 directs keratinocyte‐specific and differentiation‐specific gene expression in vitro
HUT73742A (en) Process for screening substances having a modulating effect on an interleukine-5-receptor-dependent cellular signal transmission path
BR9708256A (pt) Processo para identificar genes com expresão específica ao síto ou de síto preferido em células de marcacção específicas presentes em um ambiente de células diferente ou não daquele de sua origem e uso do mesmo
ATE297999T1 (de) Dna expression in transfizierten zellen und testverfahren in transfiziereen zellen
DK0898708T3 (da) Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays
ATE328100T1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren
NZ508103A (en) Photoinhibitory promoter
BR9916475A (pt) Células somáticas com gene prp removido emétodos de uso
Carpenter et al. Investigation of Factors Affecting BOD Measurement and Experience with the 1-Day BOD Test
Chapman et al. The different alternatively spliced isoforms of the Oct-2 transcription factor repress the involucrin promoter in a cell type-specific manner
WO1994011510A3 (en) Modulators of hematopoietic progenitor cells
ATE21114T1 (de) Dispersionen von kohlen in wasser zur verwendung als brennstoff.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition